<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53899">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404480</url>
  </required_header>
  <id_info>
    <org_study_id>PTC596-ONC-001-AST</org_study_id>
    <nct_id>NCT02404480</nct_id>
  </id_info>
  <brief_title>PTC596 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic study of PTC596 in
      patients with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>PTC596</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC596 capsules will be orally administered twice a week until disease progression or unacceptable toxicity. The starting dose is 0.65 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTC596</intervention_name>
    <arm_group_label>PTC596</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed solid malignancy that is
             metastatic or unresectable, for which standard curative measures do not exist, that
             has progressed on at least one line of standard therapy or for which no standard
             therapies exists

          -  Discontinuation of all other therapies (including other investigational drugs,
             radiotherapy, or chemotherapy) for the treatment of cancer ≥4 weeks (≥6 weeks if
             nitrosoureas, ≥12 weeks if radiotherapy) before initiation of study treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  A measured or estimated creatinine clearance (CrCl) ≥60 mL/min/1.73 m2

        Exclusion Criteria:

          -  Prior bone marrow/hematopoietic stem cell transplantation

          -  History of solid organ, bone marrow, or progenitor cell transplantation

          -  History of major surgical procedure within 28 days prior to start of study treatment

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection. Known human
             immunodeficiency virus (HIV) infection or acquired-immunodeficiency syndrome
             (AIDS)-related illness

          -  Any of the following in the past 6 months: myocardial infarction, unstable angina,
             coronary/peripheral artery bypass graft, congestive heart failure (New York Heart
             Association Class III or IV), cerebrovascular accident, transient ischemic attack,
             other arterial thromboembolic event, or pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Laskin, MD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keisha Moragne</last_name>
    <phone>908-222-7000</phone>
    <email>kmoragne@ptcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Stephens</last_name>
      <phone>617-632-6297</phone>
      <email>andrewd_stephens@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Boulton</last_name>
      <phone>919-668-0896</phone>
      <email>susan.boulton@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Annick Desjardins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Foust</last_name>
      <email>ashley.foust@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Capobianco</last_name>
      <phone>416-946-4616</phone>
      <email>stephanie.capobianco@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Philippe Bedard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 24, 2015</lastchanged_date>
  <firstreceived_date>March 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
